Angle PLC Announces Issue of Equity

Rhea-AI Summary

ANGLE plc (OTCQX:ANPCY) has issued 26,667 new ordinary shares following the exercise of employee options, increasing the total shares to 234,208,051. The new shares will begin trading on the London Stock Exchange on 9 August 2021. ANGLE is renowned for its liquid biopsy technology, the Parsortix system, which allows non-invasive cancer cell analysis and has shown significant accuracy in clinical studies, particularly for ovarian cancer. The company is pursuing FDA clearance for its system, aiming to enhance its market position in oncology diagnostics.

Positive

• Issued 26,667 new shares, increasing total shares to 234,208,051.
• The Parsortix system has demonstrated high accuracy in clinical studies (AUC-ROC of 95.1% for ovarian cancer).
• Pursuing FDA clearance aims to establish the Parsortix system as the first FDA-approved system for CTC harvesting.

Negative

• None.

Exercise of Options and Total Voting Rights

GUILDFORD, SURREY / ACCESSWIRE / August 3, 2021 / ANGLE plc (OTCQX:ANPCY) (AIM:AGL), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 26,667 new ordinary shares of £0.10 each ('New Ordinary Shares') in the Company. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

An application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted. to trading on AIM ('Admission') and it is expected that Admission will become effective, and trading will commence at 8.00 a.m. on 9 August 2021. Following Admission, the total number of Ordinary Shares in issue, and therefore the total number of voting rights, will be 234,208,051.

Contacts:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley ECM - Alice Lane, Sunila de Silva	+44 (0)20 7220 0500
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks	+44 (0) 203 705 9330
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen as being an intact cell they allow DNA, RNA and protein analysis and may provide comparable analysis to a tissue biopsy. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

The Parsortix system has a CE Mark in Europe for the indicated use and, in the United States, a De Novo Submission has been made to FDA for the Parsortix® PC1 system seeking FDA clearance with Class II Classification for use with metastatic breast cancer patients. FDA clearance is seen as the global standard. ANGLE is seeking to be the first ever FDA cleared system for harvesting CTCs for subsequent analysis.

ANGLE has also completed two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation and is currently in the process of a 200 patient clinical verification study.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 46 peer-reviewed publications and numerous publicly available posters, available on our website.

ANGLE has established clinical services laboratories in the UK and USA to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services to pharmaceutical and biotech customers for use of the Parsortix system in cancer drug trials and, once the laboratories are accredited, and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View source version on accesswire.com:
https://www.accesswire.com/658164/Angle-PLC-Announces-Issue-of-Equity

FAQ

What is the significance of ANGLE plc's share issuance on August 3, 2021?

ANGLE plc issued 26,667 new ordinary shares, increasing the total shares to 234,208,051, which may dilute existing shareholders' equity.

When will the new shares of ANGLE plc be available for trading?

The new shares will be available for trading on the London Stock Exchange starting at 8:00 a.m. on August 9, 2021.

What is the market focus of ANGLE plc's Parsortix system?

The Parsortix system focuses on non-invasive cancer diagnostics by capturing circulating tumor cells for analysis.

What recent clinical study results has ANGLE plc achieved?

ANGLE plc's studies have shown a 95.1% accuracy rate for its ovarian cancer pelvic mass triage test, indicating its technological effectiveness.